Organocatalytic Application of Ionic Liquids: [bmim][MeSO4] as a Recyclable Organocatalyst in the Multicomponent Reaction for the Preparation of Dihydropyrimidinones and -thiones
substitution in the latter. The ionic liquid can be recovered and reused for five consecutive reactions without significant loss of catalytic efficiency. The applicability of the methodology for large-scale reaction highlights its potential for bulk synthesis. ionic liquid - organocatalyst - multicomponent reaction - dihydropyrimidinone - dihydropyrimidinethione
The Biginelli Reaction with an Imidazolium-Tagged Recyclable Iron Catalyst: Kinetics, Mechanism, and Antitumoral Activity
作者:Luciana M. Ramos、Bruna C. Guido、Catharine C. Nobrega、José R. Corrêa、Rafael G. Silva、Heibbe C. B. de Oliveira、Alexandre F. Gomes、Fábio C. Gozzo、Brenno A. D. Neto
DOI:10.1002/chem.201204314
日期:2013.3.25
The present work describes the synthesis, characterization, and application of a new ion‐tagged iron catalyst. The catalyst was employed in the Biginelli reaction with impressive performance. High yields have been achieved when the reaction was carried out in imidazolium‐based ionicliquids (BMI⋅PF6, BMI⋅NTf2, and BMI⋅BF4), thus showing that the ionic‐liquid effects play a role in the reaction. Moreover
Trimethylsilyl Chloride: A Facile and Efficient Reagent for One‐Pot Synthesis of 3,4‐Dihydropyrimidin‐2(1<i>H</i>)‐ones
作者:Yulin Zhu、Yuanjiang Pan、Shenlin Huang
DOI:10.1081/scc-200028607
日期:2004.1
Trimethylsilyl chloride (TMSCl) was used as a Lewis acid to efficiently perform one-pot, three-components, Biginelli condensation reactions of aldehydes, 1,3-dicarbonyl compounds, and urea or thiourea. This resulted in simple one-pot synthesis of the corresponding 3,4-dihydropyrimidin-2(1H)-ones at room temperature with excellent yield.
Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases
申请人:Hannus Michael
公开号:US20090324580A1
公开(公告)日:2009-12-31
The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.
USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES
申请人:HANNUS MICHAEL
公开号:US20120276121A1
公开(公告)日:2012-11-01
The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.